Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04KHY
|
|||
| Former ID |
DNC001362
|
|||
| Drug Name |
Spiroglumide
|
|||
| Synonyms |
UNII-EZS5V8UN4Y; 137795-35-8; EZS5V8UN4Y; CHEMBL283820; CR-2194; (4R)-5-(8-azaspiro[45]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid; (R)-gamma-(3,5-Dichlorobenzamido)-delta-oxo-8-azaspiro(45)decane-8-valeric acid; Spiroglumide [INN]; AC1Q3LYL; AC1L24DH; SCHEMBL7920324; CTK0H9697; DTXSID60160311; FJCZHMXAGBYXHJ-QGZVFWFLSA-N; BDBM50048772; (R)-5-(8-Aza-spiro[45]dec-8-yl)-4-(3,5-dichloro-benzoylamino)-5-oxo-pentanoic acid; Radaxafine HCl
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Stomach disease [ICD-11: DA43-DA4Y; ICD-10: K30-K31] | Phase 2 | [1] | |
| Neuropathic pain [ICD-11: 8E43.0] | Discontinued in Phase 1 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26Cl2N2O4
|
|||
| Canonical SMILES |
C1CCC2(C1)CCN(CC2)C(=O)C(CCC(=O)O)NC(=O)C3=CC(=CC(=C3)Cl)Cl
|
|||
| InChI |
1S/C21H26Cl2N2O4/c22-15-11-14(12-16(23)13-15)19(28)24-17(3-4-18(26)27)20(29)25-9-7-21(8-10-25)5-1-2-6-21/h11-13,17H,1-10H2,(H,24,28)(H,26,27)/t17-/m1/s1
|
|||
| InChIKey |
FJCZHMXAGBYXHJ-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 137795-35-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress medicinal chem PMC37H. Page(48). | |||
| REF 2 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||
| REF 3 | Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.